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Background: This study was undertaken to evaluate the beneficial effects of a modified prescription of Sutaehwan
named Sutaehwan-Gami (SG), created by adding Rhizoma dioscoreae and Carthami semen to Sutaehwan, on
menopausal symptoms.
Methods: To evaluate the estrogenic effect of SG, we first examined estrogen receptor (ER) activation by SG
treatment in breast adenocarcinoma cells and confirmed the estrogenic effect of SG in vivo ovariectomized rats.
The animals were randomized into four groups: Sham operated group (Sham), saline treated ovariectomized group
(OVX), SG treated group (SG) and raloxifene treated group (RLX). Animals were provided with SG at a dose of 500
mg/kg bw/day and RLX at a dose of 5.4 mg/kg bw/day with standard rat pellets for 3 months.
Results: SG significantly increased ERα phosphorylation, and its downstream effectors, extracellular signal-regulated
kinase (ERK) and protein kinase B (Akt) phosphorylation in breast adenocarcinoma cells. Treatment with SG reversed
ovariectomy-induced uterine weight reduction and weight gain. Decreases in the levels of GOT and GPT were
observed in the SG group. The significantly reduced E2β level in OVX rats was raised by treatment with SG.
Moreover, SG significantly increased the phosphorylation levels of ERK and Akt in the uterus.
Conclusion: Taken together, these data indicate that SG has phytoestrogen-like properties through ERK and Akt
activation, implying that it could be protective and beneficial for the management of menopausal symptoms.
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Menopause is an important physiological event, with the
cessation of menstruation indicating the end of a woman’s
reproductive lifespan. Women in menopausal transition ex-
perience a variety of symptoms such as hot flashes, sweating,
anxiety, depression, mood swings, sleep disorders, vaginal
dryness and joint pain; all of these symptoms are due to the
cessation of ovarian estrogen production [1]. The major
source of estrogen after menopause is through the conver-
sion of adrenal androgen to estrogen by the enzyme aroma-
tase in the peripheral tissues, but estrogen is maintained at a
very low level due to aromatase inhibitors [2].
Estrogen plays multiple biological functions. It is required
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reproduction in any medium, provided the ortissues. Estrogen also controls energy homeostasis, core
body temperature, bone remodeling and neuroprotection.
Estrogen exerts its effects via the known estrogen receptors
of ERα and ERβ by either nuclear- or membrane-mediated
signaling mechanism depending on its target tissue [3].
Upon interaction with estrogen, receptors undergo struc-
tural changes to promote gene transcription. At the same
time, estrogen triggers various protein kinase pathways
including the MAPK/ERK and PI3K/Akt pathways [3]. Ac-
tivation of these signaling cascades leads to the phosphoryl-
ation of the AF-1 domain of ERα [4].
Approximately 40% of women suffering such symptoms
seek medical attention from health care providers for the
management of menopausal symptoms [5]. Following the re-
port from the Heart and Estrogen/progestin Replacement
Study [6] that demonstrated an increased risk of
cardiovascular disease and breast cancer among women ran-
domized to hormone therapy and subsequent publication in-
dicating a link between estrogen therapy and endometrial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Prescription of Sutaewhan-Gami
Components Part used Amount (g)
Semen Cuscutae Seed 16
Cuscuta chinensis L.
Ramulus Taxilli Stem and branch 8
Taxillus chinensis De. (Loranthaceae)
Radix Dipsaci Root 8
Dried root of Dipsacus asperoides
Colla Corii Asini Donkey hide 8
Equus asinus L. (Equidae)
Rhizoma Dioscoreae Root 16
Rhizome of Disoscorea opposita Thunb.
(Fam. Dioscoreaceae).
Carthami Semen Flower 8
Carthamus tinctorius L. (Asteraceae).
Total amounts 64
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mones and turn to alternative approaches for relief of meno-
pausal symptoms. Herbal mixtures, in decoction or pill
form, are one such alternative therapy, and the effects of de-
coction or pill can be shown after total and final reaction by
their constituent compounds when administered to humans.
According to traditional Chinese medicine theory,
both menopausal symptoms and threatened abortion are
caused by kidney-liver weakness due to a deficiency of
essence with accompanying yin-yang imbalance and organ
disharmony [8]. Herbal formulas classified as kidney/liver-
tonifying are thus considered suitable for the management
of menopausal symptoms. Sutaehwan, which contains the
four herbs Semen cuscutae (Dodder seed), Ramulus taxilli
(Taxillus twig), Radix dipsaci (Himalayan teasel root) and
Colla corii asini (Donkey-hide gelatin), has been used in
Korea for the treatment of abortus habitualis including
fetal restlessness in the uterus [9]. Semen cuscutae (Dod-
der seed) has been found to stimulate the reproductive
system and reproductive endocrine function in male rats
[10]. Moreover, it has shown a phytoestrogenic effect in
MCF-7 cells [11]. Ramulus taxilli is traditionally used to
tonify the kidneys and nourish the blood [9]. Radix dipsaci
is proposed to enhance bone strength and has shown
osteoprotective effect in ovariectomized rats [12]. Colla
corii asini has long been used for tonifying the liver blood,
arresting bleeding and supplementing the kidney yin fluid
[9]. Since obesity is a common problem encountered in
postmenopausal women as a result of reduced estrogen
level [13], our study adopted a modified prescription,
Sutaehwan-Gami (SG), that comprised sutaehwan with an
addition of Rhizoma dioscoreae (yam), which has shown
antiobesity and antihyperlipidemic activities [14,15], and
Carthami semen (safflower seed) which is suggested to
improve blood circulation to remove blood stasis and pro-
mote menstruation, and which exhibited lipid-lowering
effects in humans with hyperlipidemia [16]. Our hypoth-
esis is that Sutaehwan-Gami, consisting of six herbs, will
strengthen kidney and liver function by nourishing the de-
ficient essence in these organs, and will replace decreased
estrogen and prevent the obesity related to menopause.
Our study aimed to determine whether SG has any
estrogen-like properties since there have been no previ-
ous studies on the benefits of SG for menopausal syn-
drome. In the present study, ovariectomized rat was
used as an animal model for menopause and we investi-
gated the effect of SG on serum, body weight and uterus.
We additionally evaluated the phosphorylation of ERα
and ERK and Akt in vivo and in vitro.
Methods
Preparation of Sutaehwan-Gami
Sutaehwan-Gami, a dried decoction of a mixture of six
herbs as listed in Table 1, was obtained from the Collegeof Oriental Medicine of Dongguk University. A total of
64 g of herbs was added to 500 ml of water which was
then boiled for 2 hr. The decoction was then filtered,
lyophilized and stored at 4°C.Cell culture
MCF-7 human breast cancer cells were purchased from
the American Type Culture Collection (ATCC, Manassas,
VA, USA). Cells were cultured in DMEM (WelGENE,
Daegu, Korea) medium supplemented with 10% fetal
bovine serum (WelGENE, Daegu, Korea), 100 unit/ml
penicillin (WelGENE, Daegu, Korea) and 100 μg/ml
streptomycin (WelGENE, Daegu, Korea). The cells were
maintained in a humidified atmosphere containing 5%
CO2 at 37°C. Cells were then treated with SG at 1 μg/ml
for the indicated time (5, 10, 30, 60 and 120 min) to meas-
ure phosphorylation of ERα/ERK/Akt.Cytotoxicity assay
Cell viability was determined using 3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, Sigma,
USA) assay. In brief, MCF-7 cells were seeded on 24-
well plates at a density of 5×105 cells/well and treated
with various concentrations (0.01, 0.1, 1.0, 5.0 and 10
μg/ml) of SG for 48 h. The medium was removed and
the cells were incubated with 2 mg/ml of MTT solution.
After incubation for 4 h at 37°C and 5% CO2, the super-
natants were removed and dimethyl sulfoxide (DMSO,
Sigma, USA) was added. The reactants were measured
in terms of optical density (OD) at 590 nm with a micro-
plate reader (UV max, Molecular Devices, USA). The
optical densities were converted into percentages using
the following formula:
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100. Negative control cells were treated with complete
DMEM alone.
Western blotting analysis
Thirty micrograms of cell lysates were electrophoresed
in SDS-polyacrylamide gels (SDS-PAGE) and transferred
to nitrocellulose membranes, which were then incubated
with anti-phospho ERα (Ser118), anti-ERα, anti-phospho
Akt (Thr308), anti-Akt, and anti-phospho ERK1/ERK2
(Thr202/Tyr204), anti-ERK1/ERK2 (Cell signaling, USA)
antibodies for 16 h at 4°C. After washing with TBS-T
(0.05%), the blots were incubated with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG,
and the bands were visualized using the ECL system
(Pierce Biotechnology, Rockford, IL, USA). Band images
were obtained by using a Molecular Imager ChemiDoc
XRS+ (Bio-Rad, Hercules, CA, USA) and band intensity
was analyzed using Image Lab™ software version 2.0.1
(Bio-Rad).
Experimental animals
Protocols for animal use were reviewed and approved by
the Institutional Animal Care and Use Committee at the
Dongguk University Ilsan Hospital (No. 2010–0530) and
were in accordance with National Institute of Health
guidelines. Healthy Wistar strain albino female rats
(200-250 g, 8 weeks old) were obtained from OrientBio
(Seoul, Korea) and were allowed 1 week for quarantine
and acclimatization. Animals were housed under condi-
tions of constant temperature (22±1°C), relative humid-
ity (55±1%) and 12 h light/12 h dark cycle (light on at
7:00 am). They were housed in polycarbonate cages and
given tap water and commercial rodent chow (Samyang
Feed, Daejeon, Korea) ad libitum. The rats were blindly
randomized into four groups, each group containing ten
rats: sham operated group (Sham), saline treated ovar-
iectomized group (OVX), Sutaehwan-Gami treated group
(SG) and raloxifene treated group (RLX). We provided the
animals with SG at a dose of 500 mg/kg bw/day and RLX
at a dose of 5.4 mg/kg bw/day with standard rat pellets for
3 months. In the sham group, rats were operated but the
ovaries were not removed. Treatment started 1 week after
bilateral ovariectomy under anesthesia with 3% sodium
pentobarbital. One day after 3 month treatment, the rats
were anesthetized with i.p. injection of Rompun (0.04 ml/
100 g) and Zoletil (0.04 ml/100 g). The animals were
quickly dissected and cardiac blood, ovaries and uteri were
collected for further analyses. Blood samples were allowed
to clot at room temperature and the serum was separated
by centrifuging at 400 g for 15 min. Body weight (BW)
was recorded on the last day of the experiment. The uteri
were removed and adhering fats were trimmed away. The
uterine index (UI, %) was calculated by dividing theuterine weight by body weight. All specimens and serum
samples were stored at −80°C until used for further assays.Laboratory measurement
Serum concentrations of total cholesterol (TC), high
density lipoprotein (HDL) cholesterol, triglyceride (TG),
glucose, glutamic oxaloacetic transaminase (GOT), glu-
tamic pyruvic transaminase (GPT) were measured by
enzymatic methods using commercial assay kit (Asan
Pharm., Seoul, Korea). The calcium (Ca) and phos-
phorus (P) levels were measured by colorimetric assay
kits (Biovision, USA). Alkaline phosphatase (ALP) and
estradiol-17β (E2β) concentrations were determined
using the BioVision assay kit (BioVision, USA) and
Assay Design EIA kit (Assay Design, Ann Arbor, MI,
USA), respectively. Nitric oxide (NO) is rapidly oxidized
to nitrite and nitrate, which can be used to determine
NO production. Nitric oxide colorimetric assay kit (Bio-
vision, USA) was used to measure the total nitrate/ni-
trite in the samples. Measurement was carried out
according to manufacturer protocol.Histological analysis
Uterine tissue specimens were fixed in 10% formalin for
at least 24 h at room temperature. After fixation, tissues
were dehydrated in graded ethanol, cleared in xylene,
and embedded in paraffin. Thin sections (4 μm) were
mounted on glass slides, dewaxed, rehydrated to distilled
water, and stained with hematoxylin, and eosin. As part
of the histological evaluation, all slides were examined
by a pathologist, without knowledge of the previous
treatment, under a light microscope.Data analysis
Results were given as mean ± S.E. or mean ± S.D. Data
were analyzed using one-way analysis of variance
(ANOVA) followed by Tukey’s post hoc test for multiple
comparisons where appropriate. A p-value of 0.05 or less
was considered as indicative of a significant difference.Results
Effect of SG on cell viability
The potential cytotoxic effect of SG was investigated by
determining its effect on the viability of a human breast
adenocarcinoma cell line, MCF-7 cells. Cells were trea-
ted with SG at concentrations of 0.01, 0.1, 1.0, 5.0 and
10.0 μg/ml. After 48 h SG treatment, cell death was
examined by MTT assay. SG showed no significant cyto-
toxicity by 5 μg/ml of SG but treatment with the highest
dose (10.0 μg/ml) of SG reduced cell viability by 74.51 ±
7.1% (Figure 1).
Figure 1 Effect of SG on cell viability. MCF-7 cells were treated
with different concentrations of SG for 48 hours. Cell viability was
determined by MTT assay. Data are mean ± SE of three experiments
performed in triplicate. *P < 0.05 versus 0 μg/ml.
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cells
In order to examine the estrogenic effect of SG, we mea-
sured phosphor-ERα and total-ERα from MCF-7 cells
human breast adenocarcinoma cells in the presence of
1 μg/ml SG after different time durations. As shown in
Figure 2, SG treatment led to an increased phosphoryl-
ation of ERα into the medium, which reached maximum
at 120 min. Since phosphorylation of ERα occurs through
the action of second messenger signaling pathways, the
phosphorylation levels of ERK and Akt were measured. A
dose of 1 μg/ml SG induced a rapid, 2-fold increase in the
phosphorylation state of ERK at 5 min and then gradually
increased to 60 min. Akt phosphorylation reached a
maximum level at 30 min of SG treatment and this rela-
tively high level of phosphorylation was maintained up to
2 hours.
Body weight and uterine index in ovariectomized rats
The body weights of the ovariectomized and sham rats
were not significantly different at the start of the studyFigure 2 Effect of SG on the activation of ERα, ERK and Akt in the MC
measured in MCF-7 cells which were treated with SG at 1 μg/ml for the in
anti-p- ERα/ERK/Akt or ERα/ERK/Akt antibody. The intensity of the phospho
intensity of the phosphorylated ERα/ERK/Akt band was normalized to that(data not shown). After three months, placebo-treated
OVX rats weighed 22.4% more than sham rats (P < 0.05)
despite a similar food intake (Table 2). Treatment with
raloxifene but not with SG prevented the ovariectomy-
induced weight gain (P < 0.05, versus OVX). Uterine index
was significantly reduced in the OVX group (P < 0.01, ver-
sus sham group). Treatment of ovariectomized rats with
either SG or raloxifene increased the uterine index com-
pared with the OVX group, though not significantly.
Serum biochemical markers in ovariectomized rats
The effects of SG on serum biochemical markers are
summarized in Table 2. OVX rats showed significant in-
crease of TC (P < 0.01, versus sham group), but raloxi-
fene prevented ovariectomy-induced increase in TC (P <
0.05, versus OVX). Treatment with either SG or raloxi-
fene significantly reduced the serum TG compared to
the saline-treated OVX group. Ovariectomy appears to
increase serum ALP, Ca and P levels, but these changes
did not reach statistical significance. However, treatment
of ovariectomized rats with raloxifene significantly
altered serum Ca (P < 0.05, versus OVX). The effects of
SG on liver were determined by the measurement of
serum GOT and GPT levels. The OVX group exhibited
an elevation in serum levels of GOT and GPT, indicating
liver injury. Decreases in the levels of GOT and GPT
were observed in the SG and raloxifene groups (P <
0.05, versus OVX). As expected, the significantly reduced
E2β level in saline-treated ovariectomized rats (P < 0.01,
versus sham group) was raised by treatment with either
SG or raloxifene (P < 0.05, versus OVX). NO appears to
be low with the treatment with either SG or raloxifene.
Effect of SG on phosphorylation of ERK and Akt in the
uterus of ovariectomized rats
Our study showed that ovariectomy led to an increase of
phosphorylation of ERK. To investigate the long-term ef-
fect of a herbal mixture with estrogen-like properties onF-7 cells. Total and phosphorylation state of each protein was
dicated time. The whole cell lysates were immunoblotted with
rylated or total ERα/ERK/Akt was quantified by densitometry, and the
of total ERα/ERK/Akt. *P < 0.05 versus control.









































































































































Mean ± S.D. ** P < 0.01, * P < 0.05 vs sham, †† P < 0.01, † P < 0.05 vs OVX.
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mized rats with SG for 3 months. It was found that SG
and raloxifene increased the phosphorylation levels of
ERK and Akt in the uterus (Figure 3).
Uterine morphology in ovariectomized rats
Under light microscopy, a marked atrophy of the uterus
was observed in ovariectomized rats that was about half
the size of that in sham rats (Figure 4). Even though our
study did not measure the uterine histologic parameters,
this finding might be due to decreased epithelial cell
height and myometrial thickness. A partial reversal of
uterine atrophy was seen in ovariectomized rats treated
with either SG or raloxifene, probably due to an increase
in the amount of collagen in the stroma.
Discussion
Ovariectomy is a standard surgical procedure to induce
menopause in experimental animals and ovariectomized
female rats show a dramatic cessation of ovarian func-
tion and higher risk of osteoporosis [17]. Our study
showed that those rats which were ovariectomized and
not treated with either SG or raloxifene showed a signifi-
cant decrease in uterine weight compared to those rats
which underwent only sham operation. The reduction ofFigure 3 Effect of SG on the activation of ERK and Akt. Ovariectomized
lysates were immunoblotted with anti-p-ERK, anti p-Akt, ERK antibody and
and the intensity of the phosphorylated ERK or Akt band was normalized tuterine weight was due to an atrophy of endometrium
resulting from a lack of hormones secreted by the ovar-
ies. Black et al. [18] have described further evidence of
reduced uterine weight by the reduction of uterine epi-
thelial height, uterine myometrial thickness and uterine
stromal expansion. Recent data show that ovariectomy
also caused atrophy of the vaginal epithelium in rats
[19]. However the administration of SG to ovariecto-
mized rats for three months appeared to increase the
weight of the uterus, mainly due to lack of uterine atro-
phy compared to the placebo-treated ovariectomized
rats. This improvement in uterine atrophy is probably
due to the presence of biologically active phytoestrogen-
like molecules in SG. It is interesting to note that the in-
significant change of uterine weight in raloxifene-treated
ovariectomized rats seen in our study confirms the fact
that raloxifene lacks uterotrophic activity due to its anti-
estrogenic properties in the uterus [18].
Our study showed ovariectomized rats significantly
increased body weight, which was also observed in other
studies [19,20]. The effect of estrogen insufficiency on
lipid metabolism during the menopause has been well
documented since postmenopausal women receiving es-
trogen replacement therapy have been found not to dis-
play the characteristic pattern of body weight and BMIrats were treated with SG or raloxifene for 3 months. The uterine tissue
Akt antibody. The intensity of protein was quantified by densitometry
o that of total ERK or total Akt, respectively. †P < 0.05 versus OVX.
Figure 4 Effect of SG on uterine morphology in ovariectomized rats. Following three month treatment, animals were sacrificed and uterus
was removed. Formalin-fixed rat uteri were paraffin-sectioned serially into 4 μm sections to be stained with hematoxylin and eosin. A: Sham, B:
OVX, C: SG, D: RLX, Bar = 500 μm.
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bution associated with menopause [21-23]. Furthermore,
aromatase-knockout mice displayed progressive accumu-
lation of intra-abdominal adipose tissue compared with
wild type counterparts in both males and females [24,25]
demonstrating an important role for estrogen in the
maintenance of lipid homeostasis. It is thus possible that
some of the phytoestrogen-like molecules in SG were
involved in the regulation of lipid metabolism although
the prevention of ovariectomy-induced weight gain by
SG was not significant. The magnitude of the lipid me-
tabolism effect of raloxifene was more distinguishable
than that of SG.
The serum biochemical profiles in our SG- or
raloxifene-treated rats showed mixed findings. SG and
raloxifene both produced a marked reduction in serum
triglyceride concentrations. Since the administration of
estrogen to postmenopausal women increased triglycer-
ide levels [26] and changes in triglyceride levels were
negatively associated with changes in estradiol levels in
premenopausal women [27], it follows that changes in
triglyceride concentrations in our study must be related
with changes in body weight. A trend to a progressive
increase in body weight during menopausal transition is
closely associated with an increase in total cholesterol
and LDL cholesterol levels, and no change in HDL chol-
esterol levels [27]. Our ovariectomized rats showed nosignificant change in HDL concentrations. Thus loss of
female steroid hormone alone did not influence HDL
cholesterol level. While the hypocholesterolemic effect
of raloxifene was obvious, SG showed minimal lowering
of cholesterol.
Another characteristic of menopausal symptoms is
bone loss. The measurement of ALP activity can be used
as a barometer of bone formation and bone resorption
in vivo. It is common to see an increase in serum ALP
activity and subsequent DPD (deoxypyridinoline, a
breakdown product of collagen during bone resorption)
level in response to ovariectomy [28]. Our results indi-
cate that treatment with SG did not lower serum ALP
activity, suggesting that SG might not have enough po-
tent phytoestrogen-like molecules to affect the bone
turnover rate in rats.
Menopause is further associated with increased oxida-
tive stress and metabolic disorders which can cause sev-
eral age-related diseases [17]. In fact, estrogen has potent
antioxidant effects and can reduce risk factors for general
cardiovascular diseases by reducing inflammation [29].
Behr et al. [17] confirmed that ovariectomized rats pre-
sented increased plasma oxidative stress. NO controls the
vascular tone and blood flow by activating soluble guany-
late cyclase in the vascular smooth muscles. Abnormalities
in vascular NO production thus result in endothelial dys-
function [30]. The discrepancy between NO and estradiol
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effects of SG may not be mediated by an increase produc-
tion of NO in our study. Different oxidative damage para-
meters need to be analyzed by further studies to clarify this
discrepancy. It is true that the measurement of NO is
problematic due to its short half-life (~ 5 s) and its high re-
activity with other biological components [31].
Phosphorylation of ERα is enhanced in response to es-
trogen binding and through the action of second mes-
senger signaling pathway [32]. ERK and Akt are serine/
threonine protein kinase, which plays a major role in
mitogenic signaling. Here we report that SG-induced
ERα phosphorylation occurs within minutes. The in vitro
phosphorylation pattern of ERK and Akt was similar to
that of ERα. In our in vivo data, rat uterus under the influ-
ence of SG similarly mediated the phosphorylation of ERK
and Akt. These results lead to a model in which the post-
translational modification of protein kinase cascades is the
result of a transcription-independent and nongenomic ac-
tion of estrogen receptor.
Conclusion
In conclusion, SG as a dried decoction consisting of six
herbal medicines was proven to have phytoestrogen-like
properties in female ovariectomized rats. The data pre-
sented here increase our knowledge about the protective
and beneficial mechanisms of SG for menopausal symp-
toms, and it may therefore be a viable candidate com-
pound for the development of therapeutic drugs for the
management of menopausal symptoms.
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